Platelet aggregation is one of the main functions of platelets, which are the smallest blood cells in the blood, accounting for 0.3% of the blood, and are one of the important components of blood. It maintains the integrity of the capillary wall in addition to accelerating clotting function. When the endothelium is damaged, platelets adhere to each other to produce an aggregation reaction, which plays an important role in physiological hemostasis and arterial thrombosis. Malignant tumors enhance platelet aggregation. So what is the differential diagnosis of enhanced platelet aggregation? Here are some explanations. The platelet aggregation enhancement needs to be distinguished from the following symptoms 1, thrombocytosis: thrombocytosis (Primary hemorrhagic thrombocythemia) is a myeloproliferative disease in which the original unknown abnormal proliferation is accompanied by a continuous increase in platelets. 2. Shortened platelet lifespan: Platelets are fragments of blood cells and are atypical cells because they do not have a nucleus. Platelet lifespan shortening can cause thrombocytopenia. For the diagnosis of malignant tumors, the laboratory is based on cytological examination, although its specificity is high. The use of pH, CEA, ferritin, GGT and LDH in the detection of chest and abdominal fluid and serum has been very effective in identifying malignant tumors and increasing the positive rate. Patients are suggested to pay attention to the cancer signals of common malignant tumors to take the initiative to go to hospital for examination in time, which is conducive to early detection, early diagnosis and early treatment of malignant tumors.